Recombinant Human B7-H4 Protein Fc Chimera, CF
R&D Systems, part of Bio-Techne | Catalog # 8870-B7
Key Product Details
Source
HEK293
Accession #
Structure / Form
Disulfide-linked homodimer
Conjugate
Unconjugated
Applications
Bioactivity
Product Specifications
Source
Human embryonic kidney cell, HEK293-derived human B7-H4 protein
Human B7-H4 (Phe29-Ala258) Accession # Q7Z7D3 |
IEGRMD | Human IgG1 (Pro100-Lys330) |
N-terminus | C-terminus |
Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
N-terminal Sequence Analysis
Phe29
Predicted Molecular Mass
52 kDa
Activity
Measured by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocytes.
The ED50 for this effect is 0.1-0.5 μg/mL.
The ED50 for this effect is 0.1-0.5 μg/mL.
Reviewed Applications
Read 3 reviews rated 4 using 8870-B7 in the following applications:
Formulation, Preparation and Storage
8870-B7
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
Reconstitution |
Reconstitute at 100 μg/mL in PBS.
|
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: B7-H4
(4-8). Its binding to activated T cells dampens T cell responses and induces cell cycle arrest in the T cell (3-5). Reverse signaling can induce either cell cycle arrest or apoptosis in the B7-H4 expressing cell (9, 10). B7-H4 is up-regulated in several carcinomas in correlation with tumor progression and metastasis (2, 7, 11, 12). A soluble form of B7-H4 is elevated in the serum of ovarian cancer, renal cell carcinoma, and rheumatoid arthritis patients, also in correlation with advanced disease status (13-15). Soluble B7-H4 functions as a decoy molecule that blocks the inhibitory influence of B7-H4 on immune activation (15). Despite evidence for the involvement of B7-H4 in immune regulation, mice deficient in its expression do not show significant immune deficiencies, suggesting compensation by other molecules in vivo (16).
References
- Yi, K.H. and L. Chen (2009) Immunol. Rev. 229:145.
- Salceda, S. et al. (2005) Exp. Cell Res. 306:128.
- Zang, X. et al. (2003) Proc. Natl. Acad. Sci. 100:10388.
- Prasad, V.R. et al. (2003) Immunity 18:863.
- Sica, G.L. et al. (2003) Immunity 18:849.
- Kryczek, I. et al. (2006) J. Exp. Med. 203:871.
- Tringler, B. et al. (2005) Clin. Cancer Res. 11:1842.
- Xue, Q. et al. (2010) Stem Cells Dev. 19:27.
- Song, H. et al. (2008) Cancer Lett. 266:227.
- Park, G.B. et al. (2009) Immunology 128:360.
- Zang, X. et al. (2007) Proc. Natl. Acad. Sci. 104:19458.
- Krambeck, A.E. et al. (2006) Proc. Natl. Acad. Sci. 103:10391.
- Simon, I. et al. (2006) Cancer Res. 66:1570.
- Thompson, R.H. et al. (2008) Cancer Res. 68:6054.
- Azuma, T. et al. (2009) PloS Med. 6:e1000166.
- Suh, W.-K., et al. (2006) Mol. Cell. Biol. 26:6403.
Long Name
B7 Homolog 4
Alternate Names
B7H4, B7S1, B7x, Vtcn1
Gene Symbol
VTCN1
UniProt
Additional B7-H4 Products
Product Documents for Recombinant Human B7-H4 Protein Fc Chimera, CF
Product Specific Notices for Recombinant Human B7-H4 Protein Fc Chimera, CF
For research use only
Loading...
Loading...
Loading...